11 ай бұрын
3 жыл бұрын
Пікірлер
@Pankajjotriwal Ай бұрын
Is there any treatment for ewsr1 patz1 ??
@MirunaPopescuMD 2 ай бұрын
Fantastic as always! Thank you! ❤🎉
@madhuk5449 2 ай бұрын
Your videos are an eye opener. Teaches us to update. On Tuesday, in dermpedia session, you showed ALK rearranged granular cell tumour. This was awesome.
@madhuk5449 2 ай бұрын
With molecular classification, morphological interpretation is getting ambiguous / not apt.
@madhuk5449 2 ай бұрын
You are a good soul.
@madhuk5449 2 ай бұрын
Too good, thanks
@madhuk5449 2 ай бұрын
Bernie always considered DFSP as benign not sarcoma
@madhuk5449 2 ай бұрын
DF with monster cells. Is it same as Atypical dermatofibroma. Bernie called them as DF with monster cells.
@madhuk5449 2 ай бұрын
Simplified method of teaching
@MirunaPopescuMD 2 ай бұрын
Very interesting! Thank you for doing this, it is highly educational! ❤
@lamwlw 2 ай бұрын
Fascinating ! very exciting more experts using this platform to impart knowledge.
@stevennottley 2 ай бұрын
Great presentation, thank you! I'm very glad to hear that PRAME is useful in distinguishing melanoma from CCS-certainly something I'll be sharing.
@yogeshgavali9060 Жыл бұрын
Mucinous border line tumer before Historactomy ca-101 after Historactomy done then ca 19.9-199 Cea-103 Pet ct scan shows scalloping on liver, and abdominal wall some floating particles of tumer what to do next dr. Said resurgy needed still i cant understand it is malignant or benign?
@loplop02 Жыл бұрын
Extremely well organized and updated lecture, thank you very much!
@enkhtuvshinkhorolgarav Жыл бұрын
Thank you for the great lecture. Greetings from Mongolia.
@ericaahn2927 2 жыл бұрын
Dear Dr Linos, Thank you very much for a great update - nice to know pathologists are still useful!
@kaushikdasgupta4717 2 жыл бұрын
Excellent presentation Dr Linos
@joanchen8972 2 жыл бұрын
Thank you，Sir!
@lourdeshuanca6468 2 жыл бұрын
Thank you Dr Linos. Greetings from Peru
@rizzart66 2 жыл бұрын
As a Pathologist Assistant (PA-ASCP) in the United States, I recognized early on the standards we apply to breast specimens would eventually need to be applied to all cancer and suspected cancer specimens. Developing systems to identify all the needed factors (ischemic time, etc) are key. Not only for current diagnoses but for data collection and analysis. Putting this information into the pathology report in a data field (as opposed to a text field) is a first step.
@ΘεόδωροςΤζιγκαλίδης 3 жыл бұрын
Thank you for yet another remarkable and extremely useful lesson. I would like to make a question. Is diffuse positivity for p53 diagnostically helpful for the fibrosarcomatous transformation of a DFSP ? Thank you in advance.
@klinos 3 жыл бұрын
I do not usually use it. I believe the interpretation of fibrosarcomatous transformation is a morphological one. Colleagues have described p53 diffuse positivity in FS-DFSP. Everytime I used it was not helpful. I suspect if there is a diffuse positivity you should scrutinize the tumor but I would not rely on this one way or the other. I don't think you need any IHC for the interpretation of FS-DFSP and if you rely on IHC it is almost certain that eventually a mistake will happen.
@ΘεόδωροςΤζιγκαλίδης 3 жыл бұрын
@@klinos thank you for the advice.